Platelets in rheumatoid arthritis: exploring the anti-inflammatory and antithrombotic potential of TNF inhibitors

Armen Yuri Gasparyan,1 George D Kitas1,2

Manfredi et al1 explore the relationship between tumour necrosis factor α (TNFα), TNFα inhibition and platelet activation in rheumatoid arthritis (RA). Using elegant systems they demonstrate that TNFα activates platelets and promotes their proinflammatory and procoagulant actions, while TNF inhibition (TNFi) prevents platelet activation. They suggest this is a potential mechanism explaining why TNFi associates with a reduction of cardiovascular (CV) events in patients with RA, as shown in some observational studies. Should we then become interested in platelet biology in RA?

The potential role of platelets in the pathogenesis of RA and related comorbidities has, in fact, received much less attention than it deserves. Platelets are small (1–2 μm) anucleate cells that are intimately involved in thrombosis, angiogenesis, bone remodelling, inflammation and autoimmunity. Their bidirectional, damaging and protective roles across pathophysiological processes have been explored in several clinical and laboratory studies. The discovery of specific platelet markers and agonists, which target a range of membrane-bound receptors, has resulted in better understanding of their role. It is now clear that platelet reactivity throughout their short lifespan (8–10 days) is determined by megakaryopoiesis, which is regulated quantitatively by thrombopoietin; is determined by megakaryopoiesis, which is often found in the blood stream of patients with inflammatory conditions, such as RA, and it is suggested that platelet-derived microparticles along with other biological agents play a more important role in the development of synovitis than activated platelets themselves.5 Indeed, laboratory studies have demonstrated that platelets exert arthritogenic properties through the activation of the collagen glycoprotein VI receptor and subsequent shedding of microparticles.6

As effector cells derived from megakaryocytes, platelets bear a wide variety of membrane receptors of their precursors, autonomous protein-synthesising platform (messenger RNA) and the granular system of accumulated biologically active compounds (ie, α granules, dense granules, lysosomes) facilitating their involvement in diverse immune reactions. α Granules are especially rich in inflammatory cytokines, vasoactive substances, chemokines and stimulators of platelet aggregation, which are abundantly released upon platelet activation. Biological agents of platelet granules propagate inflammation, increase vascular permeability and destroy cells at inflamed sites. Such processes could be involved in the initiation and propagation of the inflammatory response and tissue destruction both in the rheumatoid joint and the vasculature and merit further investigation in RA. At exactly the opposite end, experimental and clinical studies have shown that some components of autologous platelet-rich plasma, and particularly ADP of dense granules, are capable of stimulating proliferation of chondrocytes and deposition of collagen I, thereby repairing damaged cartilage and tendons.7 8 There is, therefore, a distinct possibility of regulating various pathophysiological processes in joints and surrounding tissues by suppressing and activating platelets at different stages of the disease. A variety of specific markers of platelet activation have been tested across inflammatory rheumatic diseases; platelet count, membrane-bound P-selectin and CD40 ligand (CD40L), β-thromboglobulin, platelet factor 4 (PF4), also known as chemokine (C-X-C motif) ligand 4 (CXCL4), platelet aggregates and platelet–neutrophil complexes.5 Reactive thrombocytosis with elevation of platelet count has been suggested to be of diagnostic importance in the setting of antineutrophil cytoplasmic antibodies-associated vasculitis.9 Mildly elevated platelet count along with decreased platelet size have been viewed as a reflection of inflammatory megakaryopoiesis and activity of RA,10 while the ratio of platelets to neutrophils and lymphocytes has also been suggested to reflect rheumatoid activity.11 A recently emerged important piece of evidence points to the fact that anticitrullinated protein antibodies (ACPAs) directly stimulate the expression of P-selectin on platelets, secretion of soluble CD40L and formation of platelet aggregates.12 With the incremental increase of ACPA preceding clinically manifest RA by months and years, it is possible that insidious seropositivity and increase of C-reactive protein determine platelet activation and involvement from the earliest stages of synovial inflammation onwards.

In the era of biological therapy several lines of evidence suggest that agents inhibiting TNFα and interleukin-6 suppress disease activity and decrease platelet counts in RA.13 14 The effect of biologic disease-modifying antirheumatic drugs (bDMARDs) on platelet counts is not matched by nonbiologic DMARDs, which appear to be less effective towards megakaryopoiesis. The exception is bone marrow suppression and related thrombocytopenia as a rare occurrence of sulfasalazine therapy, which however is no longer a frontline choice in RA. Interestingly, the possible effects of bDMARDs on megakaryopoiesis may differ, with reports suggesting that tocilizumab may drop platelet counts in patients with RA more potently than adalimumab.15 This is another area that requires further investigation, as a potential side effect and also as a possible desirable effect. IL-6 is known as a physiological regulator of megakaryopoiesis acting like thrombopoietin,16 17 and blocking IL-6-related pathways may lead to anti-inflammatory and antithrombotic effects.

The present flow cytometric and electron microscopy study by Manfredi et al1 sheds light on the molecular basis of modulation of platelet activity by inflammatory cytokines and their inhibitors. The authors should be congratulated for their extensive work characterising the effects of recombinant human TNFα and the TNF inhibitor, infliximab, on platelet-rich plasma and isolated platelets of patients with RA (box 1).

One of the important messages of this study is that TNFi can only block the
TNFα-dependent activation pathways of platelets. Other pathways of platelet activation, particularly those regulated by collagen and ADP, can still continue contributing to proinflammatory and prothrombotic actions. Although platelet count was not analysed in connection with flow cytometric markers, and this can be viewed as a limitation, it is plausible that TNFα exert their effects on platelet receptors and also on platelet precursors maturing throughout megakaryopoiesis.

The authors have concentrated almost exclusively on the concept of CV comorbidity and its reduction in RA. However, the mechanisms they have described may be as important in the very essence of the disease, joint inflammation per se. It is, therefore, slightly disappointing not to see the wealth of data generated, analysed in the context of disease activity, using well-established clinical and laboratory indices.

To return to the original thesis: this study answered the question as to whether inhibition of platelet activation by TNFα translates into CV protection in RA? As the authors themselves point out it has not, due to evident design limitations such as its cross-sectional nature, small sample size, lack of long-term longitudinal follow-up and inability to control for multiple potential confounders (Box 1). The study is a good reference for future studies aiming to address CV risk reduction in RA. The CV implications of antinflammatory therapies may be very important in the pathogenic mechanisms of rheumatoid synovitis and related CV comorbidity. Despite the many challenges, it merits much more research attention than it has been receiving thus far.

Contributors AYG wrote the first draft of the manuscript. GDK revised all parts, added several sections. Both authors approved the final version.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

To cite Gasparyan AY, Kitas GD. Ann Rheum Dis Published Online First: [please include Day Month Year] doi:10.1136/annrheumdis-2015-208442

Received 24 February 2016

Accepted 10 March 2016

http://dx.doi.org/10.1136/annrheumdis-2015-208442

Box 1 New knowledge and limitations of the study by Manfredi et al1

Important new data
- Tumour necrosis factor α (TNFα) depletes α granules of rheumatoid platelets (TNFα receptor 1-mediated effect).
- TNFα leads to the expression of P-selectin, CD40L, tissue factor, fibrinogen binding to rheumatoid platelets and forming platelet–neutrophil complexes (TNFα receptor 2-mediated effect).
- Infliximab abrogates TNFα-specific platelet-activating effects but does not affect several other activation pathways in rheumatoid platelets.
- Platelets in rheumatoid arthritis (RA) are more activated than in coronary artery disease and osteoarthritis.

Limitations
- The relationships between platelet markers and cardiovascular risk/comorbidities in RA were not explored.
- Platelet count, a proxy of inflammatory megakaryopoiesis, was not analysed in relation to flow cytometric markers of platelet activation in RA.